Mayumi Fujita
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 30 | 2023 | 629 | 5.800 |
Why?
| Skin Neoplasms | 14 | 2021 | 761 | 2.210 |
Why?
| Neoplastic Stem Cells | 11 | 2020 | 334 | 2.060 |
Why?
| Interleukin-1 | 10 | 2022 | 966 | 1.740 |
Why?
| Aldehyde Dehydrogenase | 5 | 2019 | 134 | 1.540 |
Why?
| T-Lymphocytes, Regulatory | 6 | 2023 | 342 | 1.540 |
Why?
| Cysteine | 2 | 2020 | 171 | 0.920 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2021 | 144 | 0.920 |
Why?
| Inflammasomes | 3 | 2020 | 115 | 0.890 |
Why?
| Cell Transformation, Neoplastic | 2 | 2018 | 312 | 0.880 |
Why?
| Ultraviolet Rays | 3 | 2020 | 366 | 0.830 |
Why?
| Antineoplastic Agents | 10 | 2021 | 1895 | 0.810 |
Why?
| Vitiligo | 4 | 2020 | 52 | 0.800 |
Why?
| Neoplasms, Second Primary | 1 | 2023 | 94 | 0.790 |
Why?
| Cell Line, Tumor | 18 | 2019 | 2725 | 0.780 |
Why?
| Nitric Oxide | 2 | 2019 | 824 | 0.780 |
Why?
| Aldehyde Oxidoreductases | 2 | 2019 | 31 | 0.770 |
Why?
| Forkhead Transcription Factors | 1 | 2022 | 171 | 0.760 |
Why?
| Mice | 30 | 2022 | 14916 | 0.740 |
Why?
| Cryopyrin-Associated Periodic Syndromes | 1 | 2020 | 6 | 0.730 |
Why?
| Melanocytes | 7 | 2020 | 55 | 0.720 |
Why?
| Keratinocytes | 3 | 2021 | 216 | 0.710 |
Why?
| Skin | 3 | 2020 | 659 | 0.710 |
Why?
| Pancreatic Neoplasms | 2 | 2019 | 732 | 0.690 |
Why?
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2019 | 33 | 0.650 |
Why?
| Hyperpigmentation | 1 | 2019 | 11 | 0.640 |
Why?
| MicroRNAs | 2 | 2023 | 601 | 0.640 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2020 | 278 | 0.630 |
Why?
| CDC2 Protein Kinase | 1 | 2018 | 25 | 0.620 |
Why?
| Adenosine Triphosphate | 1 | 2020 | 431 | 0.620 |
Why?
| SOXB1 Transcription Factors | 1 | 2018 | 61 | 0.610 |
Why?
| Animals | 35 | 2022 | 31762 | 0.590 |
Why?
| Phenotype | 3 | 2022 | 2812 | 0.590 |
Why?
| Drug Resistance, Neoplasm | 6 | 2020 | 642 | 0.580 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 299 | 0.570 |
Why?
| Interleukin-1beta | 6 | 2021 | 370 | 0.560 |
Why?
| Neoplasm Invasiveness | 3 | 2019 | 445 | 0.550 |
Why?
| RNA, Messenger | 5 | 2019 | 2557 | 0.540 |
Why?
| Inflammation | 6 | 2019 | 2481 | 0.540 |
Why?
| Signal Transduction | 10 | 2021 | 4522 | 0.540 |
Why?
| Dendritic Cells | 4 | 2016 | 436 | 0.510 |
Why?
| Sulfonamides | 6 | 2020 | 445 | 0.510 |
Why?
| Skin Pigmentation | 3 | 2020 | 39 | 0.480 |
Why?
| Humans | 54 | 2023 | 114757 | 0.480 |
Why?
| Mice, Nude | 7 | 2021 | 635 | 0.480 |
Why?
| Heavy Ion Radiotherapy | 1 | 2014 | 1 | 0.480 |
Why?
| Immune Tolerance | 2 | 2015 | 328 | 0.470 |
Why?
| Nitrophenols | 5 | 2017 | 32 | 0.470 |
Why?
| Psoriasis | 3 | 2021 | 74 | 0.470 |
Why?
| rhoA GTP-Binding Protein | 1 | 2014 | 73 | 0.460 |
Why?
| Biphenyl Compounds | 5 | 2017 | 50 | 0.460 |
Why?
| Biomarkers, Tumor | 5 | 2021 | 1053 | 0.460 |
Why?
| Melanoma, Experimental | 2 | 2021 | 89 | 0.460 |
Why?
| Adaptive Immunity | 1 | 2014 | 156 | 0.430 |
Why?
| Retinal Dehydrogenase | 3 | 2019 | 41 | 0.430 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2021 | 213 | 0.430 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 399 | 0.420 |
Why?
| Proto-Oncogene Proteins B-raf | 4 | 2021 | 193 | 0.410 |
Why?
| Side-Population Cells | 1 | 2012 | 9 | 0.410 |
Why?
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 1147 | 0.410 |
Why?
| Cell Separation | 1 | 2013 | 292 | 0.410 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 330 | 0.410 |
Why?
| Camellia sinensis | 1 | 2011 | 2 | 0.390 |
Why?
| Cytoskeletal Proteins | 1 | 2012 | 145 | 0.390 |
Why?
| Polyphenols | 1 | 2011 | 16 | 0.390 |
Why?
| Neoplasm Proteins | 2 | 2021 | 385 | 0.380 |
Why?
| Catechin | 1 | 2011 | 23 | 0.380 |
Why?
| Complement C1q | 1 | 2011 | 37 | 0.380 |
Why?
| Apoptosis | 9 | 2021 | 2369 | 0.370 |
Why?
| Pemphigus | 1 | 2011 | 8 | 0.370 |
Why?
| Desmoglein 3 | 1 | 2011 | 17 | 0.370 |
Why?
| Paraneoplastic Syndromes | 1 | 2011 | 12 | 0.370 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2011 | 447 | 0.370 |
Why?
| Ubiquitin | 1 | 2010 | 57 | 0.360 |
Why?
| Gene Expression Profiling | 3 | 2018 | 1521 | 0.360 |
Why?
| Cannabidiol | 2 | 2022 | 60 | 0.360 |
Why?
| Disease Models, Animal | 8 | 2021 | 3542 | 0.350 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2010 | 134 | 0.350 |
Why?
| Histiocytosis | 1 | 2010 | 8 | 0.350 |
Why?
| Caspase 2 | 1 | 2009 | 14 | 0.350 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2020 | 22 | 0.340 |
Why?
| Naphthoquinones | 1 | 2009 | 17 | 0.330 |
Why?
| Ultraviolet Therapy | 2 | 2020 | 16 | 0.330 |
Why?
| Carcinoma, Merkel Cell | 1 | 2009 | 17 | 0.330 |
Why?
| Membrane Proteins | 3 | 2016 | 1022 | 0.320 |
Why?
| Carcinoma, Basal Cell | 1 | 2010 | 68 | 0.320 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2009 | 100 | 0.310 |
Why?
| Female | 22 | 2021 | 59507 | 0.300 |
Why?
| Radiation-Protective Agents | 1 | 2008 | 26 | 0.300 |
Why?
| Imidazoles | 1 | 2009 | 211 | 0.300 |
Why?
| Xenograft Model Antitumor Assays | 6 | 2021 | 706 | 0.300 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 174 | 0.300 |
Why?
| Cytokines | 3 | 2022 | 1843 | 0.300 |
Why?
| Dacarbazine | 3 | 2012 | 101 | 0.300 |
Why?
| Cell Proliferation | 5 | 2021 | 2196 | 0.290 |
Why?
| Neoplasms | 2 | 2020 | 2105 | 0.290 |
Why?
| Mice, Transgenic | 5 | 2021 | 1951 | 0.290 |
Why?
| Enzyme Activation | 3 | 2020 | 787 | 0.280 |
Why?
| Cancer Vaccines | 1 | 2007 | 138 | 0.270 |
Why?
| Receptors, Interleukin-1 | 4 | 2020 | 227 | 0.260 |
Why?
| Models, Animal | 1 | 2008 | 345 | 0.260 |
Why?
| Nitric Oxide Synthase | 2 | 2019 | 209 | 0.260 |
Why?
| Antigens, Neoplasm | 1 | 2007 | 222 | 0.260 |
Why?
| Neutrophils | 1 | 2011 | 1163 | 0.260 |
Why?
| Carrier Proteins | 1 | 2009 | 696 | 0.260 |
Why?
| Immunity, Innate | 3 | 2016 | 723 | 0.250 |
Why?
| Mice, Hairless | 2 | 2020 | 74 | 0.250 |
Why?
| Isoenzymes | 2 | 2018 | 285 | 0.240 |
Why?
| Prognosis | 3 | 2023 | 3334 | 0.240 |
Why?
| Antioxidants | 1 | 2008 | 530 | 0.230 |
Why?
| Saccharomyces cerevisiae | 1 | 2007 | 477 | 0.220 |
Why?
| Dermatitis, Atopic | 2 | 2020 | 307 | 0.220 |
Why?
| Mice, Inbred C57BL | 5 | 2019 | 4710 | 0.220 |
Why?
| Up-Regulation | 2 | 2019 | 812 | 0.210 |
Why?
| CTLA-4 Antigen | 1 | 2023 | 77 | 0.210 |
Why?
| Mutation | 5 | 2020 | 3350 | 0.210 |
Why?
| Cellular Reprogramming | 2 | 2020 | 84 | 0.210 |
Why?
| Dermatitis | 1 | 2022 | 17 | 0.210 |
Why?
| Australia | 1 | 2023 | 207 | 0.200 |
Why?
| Kaplan-Meier Estimate | 2 | 2019 | 815 | 0.200 |
Why?
| Receptor, EphB4 | 1 | 2022 | 23 | 0.200 |
Why?
| Jurkat Cells | 1 | 2022 | 128 | 0.200 |
Why?
| Ephrin-B2 | 1 | 2022 | 36 | 0.200 |
Why?
| Flow Cytometry | 3 | 2015 | 1086 | 0.200 |
Why?
| AMP-Activated Protein Kinases | 1 | 2023 | 175 | 0.200 |
Why?
| Chemotaxis | 2 | 2014 | 130 | 0.190 |
Why?
| Male | 13 | 2020 | 55579 | 0.190 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 33 | 0.190 |
Why?
| Hair Follicle | 2 | 2020 | 44 | 0.190 |
Why?
| Alcohol Oxidoreductases | 1 | 2021 | 38 | 0.190 |
Why?
| Anti-Inflammatory Agents | 2 | 2022 | 450 | 0.190 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 37 | 0.190 |
Why?
| MAP Kinase Kinase 1 | 1 | 2021 | 66 | 0.190 |
Why?
| Protein Interaction Maps | 1 | 2020 | 34 | 0.180 |
Why?
| Pruritus | 1 | 2020 | 60 | 0.180 |
Why?
| Adult Stem Cells | 1 | 2020 | 32 | 0.180 |
Why?
| RNA, Small Interfering | 2 | 2012 | 543 | 0.180 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 58 | 0.170 |
Why?
| S Phase Cell Cycle Checkpoints | 1 | 2020 | 5 | 0.170 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 8 | 0.170 |
Why?
| Aniline Compounds | 1 | 2020 | 70 | 0.170 |
Why?
| Leupeptins | 2 | 2010 | 9 | 0.170 |
Why?
| Cell Plasticity | 1 | 2020 | 23 | 0.170 |
Why?
| Proteasome Inhibitors | 2 | 2010 | 40 | 0.170 |
Why?
| Interleukin-1 Receptor Accessory Protein | 1 | 2019 | 9 | 0.170 |
Why?
| beta Catenin | 2 | 2020 | 220 | 0.170 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2021 | 689 | 0.170 |
Why?
| Antibodies, Blocking | 1 | 2019 | 32 | 0.170 |
Why?
| Tail | 1 | 2019 | 29 | 0.160 |
Why?
| Piperazines | 6 | 2021 | 311 | 0.160 |
Why?
| Peritonitis | 1 | 2019 | 76 | 0.160 |
Why?
| Nitrofurans | 1 | 2018 | 1 | 0.160 |
Why?
| Interleukins | 1 | 2020 | 236 | 0.160 |
Why?
| Hydroxybenzoates | 1 | 2018 | 10 | 0.160 |
Why?
| Aged | 6 | 2020 | 19094 | 0.160 |
Why?
| Histones | 1 | 2023 | 536 | 0.160 |
Why?
| Lung Neoplasms | 1 | 2011 | 2199 | 0.150 |
Why?
| Heterografts | 1 | 2018 | 117 | 0.150 |
Why?
| Fluorescent Antibody Technique | 1 | 2019 | 396 | 0.150 |
Why?
| Congresses as Topic | 1 | 2019 | 196 | 0.150 |
Why?
| Head and Neck Neoplasms | 1 | 2022 | 436 | 0.150 |
Why?
| Zinc Finger Protein GLI1 | 1 | 2017 | 21 | 0.150 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2020 | 182 | 0.150 |
Why?
| Neoplasm Staging | 2 | 2012 | 1176 | 0.140 |
Why?
| MAP Kinase Signaling System | 1 | 2019 | 276 | 0.140 |
Why?
| Stress, Physiological | 1 | 2020 | 379 | 0.140 |
Why?
| Protein Transport | 1 | 2018 | 396 | 0.140 |
Why?
| Biopsy | 2 | 2011 | 1040 | 0.140 |
Why?
| Computational Biology | 1 | 2020 | 530 | 0.140 |
Why?
| Drug Synergism | 5 | 2017 | 316 | 0.140 |
Why?
| Overweight | 1 | 2020 | 471 | 0.140 |
Why?
| Drug Therapy, Combination | 2 | 2016 | 954 | 0.140 |
Why?
| Haptens | 2 | 2014 | 21 | 0.140 |
Why?
| Transforming Growth Factor beta | 1 | 2019 | 449 | 0.140 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1340 | 0.140 |
Why?
| Dermatitis, Contact | 2 | 2014 | 23 | 0.130 |
Why?
| Cell Survival | 3 | 2017 | 1021 | 0.130 |
Why?
| Mice, Knockout | 2 | 2021 | 2582 | 0.130 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 854 | 0.130 |
Why?
| Biomedical Research | 2 | 2019 | 585 | 0.130 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 521 | 0.130 |
Why?
| B-Lymphocytes | 1 | 2020 | 769 | 0.130 |
Why?
| Oligopeptides | 1 | 2016 | 234 | 0.120 |
Why?
| Fenretinide | 1 | 2014 | 7 | 0.120 |
Why?
| Dinitrofluorobenzene | 1 | 2014 | 7 | 0.120 |
Why?
| Proteomics | 1 | 2020 | 843 | 0.120 |
Why?
| Tumor Microenvironment | 2 | 2022 | 433 | 0.120 |
Why?
| Ethanol | 1 | 2019 | 548 | 0.120 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 1314 | 0.120 |
Why?
| Cell Line | 1 | 2020 | 2639 | 0.120 |
Why?
| Phosphorylation | 1 | 2018 | 1571 | 0.120 |
Why?
| Pneumonia | 1 | 2019 | 566 | 0.110 |
Why?
| Caspases | 2 | 2012 | 245 | 0.110 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1361 | 0.110 |
Why?
| Cilia | 1 | 2015 | 162 | 0.110 |
Why?
| Viral Load | 1 | 2015 | 405 | 0.110 |
Why?
| Stem Cells | 1 | 2017 | 546 | 0.110 |
Why?
| Protein Binding | 1 | 2018 | 1897 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2019 | 1270 | 0.110 |
Why?
| Caspases, Initiator | 1 | 2012 | 18 | 0.100 |
Why?
| CARD Signaling Adaptor Proteins | 1 | 2012 | 17 | 0.100 |
Why?
| Phagocytosis | 1 | 2014 | 350 | 0.100 |
Why?
| Proto-Oncogene Proteins | 2 | 2023 | 610 | 0.100 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 347 | 0.100 |
Why?
| Crystallins | 1 | 2012 | 41 | 0.100 |
Why?
| Response Elements | 1 | 2012 | 83 | 0.100 |
Why?
| Neoplasm Transplantation | 1 | 2012 | 232 | 0.100 |
Why?
| Coloring Agents | 1 | 2012 | 72 | 0.100 |
Why?
| Cell Cycle | 1 | 2015 | 543 | 0.100 |
Why?
| Vaccinia | 1 | 2012 | 18 | 0.100 |
Why?
| Vaccinia virus | 1 | 2012 | 28 | 0.100 |
Why?
| DNA Damage | 1 | 2014 | 357 | 0.100 |
Why?
| Gene Silencing | 1 | 2012 | 172 | 0.100 |
Why?
| Mice, SCID | 1 | 2012 | 320 | 0.100 |
Why?
| Tretinoin | 1 | 2012 | 125 | 0.100 |
Why?
| Alkylating Agents | 1 | 2011 | 27 | 0.100 |
Why?
| Cells, Cultured | 1 | 2019 | 3890 | 0.100 |
Why?
| Metabolic Diseases | 1 | 2012 | 99 | 0.100 |
Why?
| Models, Biological | 1 | 2018 | 1630 | 0.100 |
Why?
| Lens, Crystalline | 1 | 2012 | 96 | 0.090 |
Why?
| Interleukin-8 | 1 | 2012 | 237 | 0.090 |
Why?
| Paclitaxel | 1 | 2012 | 190 | 0.090 |
Why?
| Mast Cells | 1 | 2012 | 117 | 0.090 |
Why?
| Genes, p16 | 1 | 2010 | 16 | 0.090 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 561 | 0.090 |
Why?
| Biomimetic Materials | 1 | 2011 | 64 | 0.090 |
Why?
| G1 Phase | 1 | 2010 | 68 | 0.090 |
Why?
| Half-Life | 1 | 2010 | 141 | 0.090 |
Why?
| Transfection | 3 | 2008 | 870 | 0.090 |
Why?
| Fatal Outcome | 1 | 2011 | 284 | 0.090 |
Why?
| Etoposide | 1 | 2010 | 148 | 0.090 |
Why?
| Lymphatic Metastasis | 1 | 2011 | 280 | 0.090 |
Why?
| Lactones | 1 | 2010 | 54 | 0.090 |
Why?
| Cell Movement | 1 | 2014 | 867 | 0.090 |
Why?
| In Vitro Techniques | 1 | 2012 | 1013 | 0.090 |
Why?
| Protein Stability | 1 | 2010 | 157 | 0.090 |
Why?
| DNA Primers | 1 | 2011 | 514 | 0.090 |
Why?
| Protease Inhibitors | 1 | 2010 | 97 | 0.090 |
Why?
| Breast Neoplasms | 1 | 2021 | 1868 | 0.090 |
Why?
| Gene Expression | 1 | 2015 | 1420 | 0.090 |
Why?
| Quality of Life | 1 | 2020 | 2358 | 0.090 |
Why?
| Middle Aged | 4 | 2020 | 26757 | 0.080 |
Why?
| Cardiovascular Diseases | 1 | 2020 | 1727 | 0.080 |
Why?
| Recombinant Proteins | 2 | 2015 | 1233 | 0.080 |
Why?
| Interleukin-6 | 3 | 2020 | 675 | 0.080 |
Why?
| Gene Deletion | 1 | 2010 | 356 | 0.080 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 42 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 743 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 797 | 0.080 |
Why?
| Knee | 1 | 2009 | 51 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 928 | 0.080 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2008 | 45 | 0.080 |
Why?
| Biopsy, Needle | 1 | 2009 | 181 | 0.080 |
Why?
| NF-kappa B | 1 | 2012 | 636 | 0.080 |
Why?
| Rare Diseases | 1 | 2009 | 89 | 0.080 |
Why?
| Pyrroles | 2 | 2021 | 183 | 0.080 |
Why?
| Lymph Node Excision | 1 | 2009 | 141 | 0.080 |
Why?
| Genes, ras | 1 | 2008 | 91 | 0.080 |
Why?
| Neovascularization, Pathologic | 1 | 2009 | 283 | 0.070 |
Why?
| MART-1 Antigen | 1 | 2007 | 10 | 0.070 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2007 | 47 | 0.070 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2008 | 171 | 0.070 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 2099 | 0.070 |
Why?
| Base Sequence | 1 | 2011 | 2118 | 0.070 |
Why?
| Macrophages | 2 | 2015 | 1261 | 0.070 |
Why?
| Cytotoxicity, Immunologic | 1 | 2007 | 195 | 0.070 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 140 | 0.070 |
Why?
| Cell Self Renewal | 2 | 2017 | 49 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2020 | 4420 | 0.070 |
Why?
| Immunoglobulin G | 1 | 2011 | 774 | 0.070 |
Why?
| Combined Modality Therapy | 1 | 2009 | 1122 | 0.070 |
Why?
| Dinitrobenzenes | 1 | 2005 | 6 | 0.070 |
Why?
| Spleen | 1 | 2007 | 484 | 0.060 |
Why?
| Down-Regulation | 2 | 2023 | 596 | 0.060 |
Why?
| Interleukin-12 | 1 | 2005 | 110 | 0.060 |
Why?
| Immunohistochemistry | 1 | 2009 | 1635 | 0.060 |
Why?
| Risk Assessment | 2 | 2015 | 2973 | 0.060 |
Why?
| Case-Control Studies | 1 | 2011 | 3005 | 0.060 |
Why?
| Interferon-gamma | 1 | 2007 | 722 | 0.060 |
Why?
| Bcl-2-Like Protein 11 | 2 | 2017 | 37 | 0.060 |
Why?
| Mixed Function Oxygenases | 1 | 2023 | 36 | 0.050 |
Why?
| Autoantibodies | 1 | 2011 | 1350 | 0.050 |
Why?
| ras Proteins | 1 | 2003 | 138 | 0.050 |
Why?
| Palmitic Acids | 1 | 2022 | 9 | 0.050 |
Why?
| Ethanolamines | 1 | 2022 | 19 | 0.050 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 2022 | 153 | 0.050 |
Why?
| Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| Acetates | 1 | 2022 | 95 | 0.050 |
Why?
| Amides | 1 | 2022 | 87 | 0.050 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2007 | 965 | 0.050 |
Why?
| Lipopolysaccharides | 2 | 2015 | 812 | 0.050 |
Why?
| Edema | 1 | 2022 | 118 | 0.050 |
Why?
| Treatment Outcome | 3 | 2020 | 9089 | 0.050 |
Why?
| HIV Infections | 1 | 2015 | 2469 | 0.050 |
Why?
| Aminopyridines | 1 | 2021 | 81 | 0.050 |
Why?
| Pyrimidinones | 1 | 2021 | 88 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2003 | 498 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2015 | 797 | 0.050 |
Why?
| Neoplasm Recurrence, Local | 2 | 2016 | 863 | 0.050 |
Why?
| Administration, Cutaneous | 1 | 2020 | 117 | 0.040 |
Why?
| Gels | 1 | 2020 | 72 | 0.040 |
Why?
| Pyridones | 1 | 2021 | 123 | 0.040 |
Why?
| Antigens, CD19 | 1 | 2020 | 91 | 0.040 |
Why?
| Potassium Channels, Voltage-Gated | 1 | 2020 | 48 | 0.040 |
Why?
| X-Rays | 1 | 2020 | 30 | 0.040 |
Why?
| rho GTP-Binding Proteins | 1 | 2020 | 61 | 0.040 |
Why?
| Erythroblasts | 1 | 2020 | 12 | 0.040 |
Why?
| A549 Cells | 1 | 2019 | 51 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2021 | 337 | 0.040 |
Why?
| Vaccination | 1 | 2007 | 1205 | 0.040 |
Why?
| Open Reading Frames | 1 | 2020 | 116 | 0.040 |
Why?
| Interleukin-33 | 1 | 2019 | 38 | 0.040 |
Why?
| Societies, Scientific | 1 | 2019 | 47 | 0.040 |
Why?
| Ovalbumin | 1 | 2019 | 161 | 0.040 |
Why?
| Point Mutation | 1 | 2020 | 216 | 0.040 |
Why?
| Uric Acid | 1 | 2019 | 148 | 0.040 |
Why?
| Prodrugs | 1 | 2018 | 42 | 0.040 |
Why?
| Pigmentation | 1 | 2018 | 55 | 0.040 |
Why?
| Cell Division | 1 | 2020 | 759 | 0.040 |
Why?
| Risk | 1 | 2020 | 815 | 0.040 |
Why?
| Pyridines | 1 | 2021 | 425 | 0.040 |
Why?
| Laser Capture Microdissection | 1 | 2017 | 23 | 0.040 |
Why?
| Molecular Structure | 1 | 2018 | 438 | 0.040 |
Why?
| HEK293 Cells | 1 | 2019 | 594 | 0.040 |
Why?
| Gene Knockout Techniques | 1 | 2017 | 99 | 0.040 |
Why?
| Neurofibromin 1 | 1 | 2016 | 22 | 0.030 |
Why?
| Self Report | 1 | 2020 | 695 | 0.030 |
Why?
| GTP Phosphohydrolases | 1 | 2016 | 66 | 0.030 |
Why?
| Mice, Inbred BALB C | 2 | 2012 | 1151 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2016 | 2321 | 0.030 |
Why?
| Amyloid Precursor Protein Secretases | 1 | 2016 | 73 | 0.030 |
Why?
| Caspase 1 | 1 | 2016 | 140 | 0.030 |
Why?
| Young Adult | 2 | 2020 | 10463 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2017 | 388 | 0.030 |
Why?
| Toll-Like Receptors | 1 | 2016 | 166 | 0.030 |
Why?
| Immobilized Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| Neutralization Tests | 1 | 2015 | 63 | 0.030 |
Why?
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 54 | 0.030 |
Why?
| Retinoids | 1 | 2014 | 31 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 82 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2015 | 257 | 0.030 |
Why?
| Complementary Therapies | 1 | 2015 | 72 | 0.030 |
Why?
| Extracellular Space | 1 | 2015 | 117 | 0.030 |
Why?
| Endotoxemia | 1 | 2015 | 82 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 262 | 0.030 |
Why?
| Adult | 3 | 2020 | 30548 | 0.030 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 256 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2020 | 2539 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 354 | 0.030 |
Why?
| Antigens, CD | 1 | 2015 | 443 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2015 | 493 | 0.030 |
Why?
| Cathelicidins | 1 | 2012 | 38 | 0.020 |
Why?
| Kaposi Varicelliform Eruption | 1 | 2012 | 22 | 0.020 |
Why?
| Survival Analysis | 1 | 2015 | 1218 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2017 | 1316 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2016 | 1691 | 0.020 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2012 | 75 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2012 | 198 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2015 | 1044 | 0.020 |
Why?
| Cohort Studies | 1 | 2020 | 4901 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2012 | 267 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2015 | 1134 | 0.020 |
Why?
| Immunization | 1 | 2012 | 401 | 0.020 |
Why?
| Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2008 | 133 | 0.020 |
Why?
| Disease Progression | 1 | 2015 | 2387 | 0.020 |
Why?
| Cell Differentiation | 1 | 2015 | 1699 | 0.020 |
Why?
| RNA Interference | 1 | 2008 | 437 | 0.020 |
Why?
| Biomarkers | 1 | 2015 | 3416 | 0.020 |
Why?
| Epidermis | 1 | 2005 | 149 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2015 | 4409 | 0.020 |
Why?
| Age Factors | 1 | 2012 | 2890 | 0.010 |
Why?
| Mitochondria | 1 | 2008 | 751 | 0.010 |
Why?
| Lymph Nodes | 1 | 2005 | 423 | 0.010 |
Why?
| Cell Hypoxia | 1 | 2003 | 220 | 0.010 |
Why?
| Adolescent | 1 | 2020 | 17808 | 0.010 |
Why?
| Child | 1 | 2020 | 18352 | 0.010 |
Why?
| Cell Culture Techniques | 1 | 2003 | 343 | 0.010 |
Why?
| Time Factors | 1 | 2011 | 6124 | 0.010 |
Why?
| Retrospective Studies | 1 | 2015 | 12515 | 0.010 |
Why?
|
|
Fujita's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|